Nos équipes de recherche et du département Innovation et Valorisation étaient présentes à l'European Society of Gene and Cell Therapy 2024 à Rome ! Cet événement a pour objectif de promouvoir la recherche fondamentale et clinique en matière de thérapie génique, de thérapie cellulaire en facilitant l'éducation, l'échange d'informations et de technologies entre les différents acteurs de la recherche 🤝 Inserm - AP-HP, Assistance Publique - Hôpitaux de Paris - Université Paris Cité #MaladiesGénétiques #RechercheMédicale
The Industrial Partnerships team of Carnot Imagine was present at the European Society of Gene and Cell Therapy 2024 in Rome, and we were thrilled to participate in this unique event, which brought together the latest advancements in innovative therapies. A few highlights from the congress: 4 educational sessions, 5 plenary sessions, 28 parallel sessions, and over 1,000 posters presented across 4 days. We are proud to share the impressive contributions from Institut Imagine, including sessions chaired by Alain Hovnanian and Annarita Miccio, as well as oral and poster presentations by Steicy Sobrino, Guillaume Mondon, Giulia Hardouin, Anne Chalumeau,Marie Hautbois, Mathilde Bonnet des Claustres, Chantal Lagresle-Peyrou, Jean-Sébastien DIANA, Emmanuelle Six and Marina Cavazzana. Congratulations to Juliette Lemoine for her recent appointment to the Early Career Researchers (ECR) board of the European Society of Gene and Cell Therapy, and a big thank you to all the Institut Imagine attendees. We also want to extend a special thanks to Arjan Lankester, who presented the AGORA initiative (Access to Gene Therapies for Rare Diseases), which Institut Imagine, alongside with HÔPITAL NECKER, is proud to be a part of. This initiative is a collaborative effort, uniting stakeholders across Europe—including academic groups, regulators, funders, patient advocacy groups, and drug developers—with the goal of creating sustainable access to innovative gene therapies for children with rare and ultra-rare diseases. Most importantly, the congress allowed us to look ahead with hope toward a brighter future for the care and cure of patients with genetic diseases.